Introducing the latest JUVÉDERM® innovation  >
EXPAND TO SEE ALL ALLERGAN BRANDS +
For Us Healthcare Professionals
Important Safety Information Patient Safety Information + Directions for use + FOR US PATIENTS Contact Us Set up Account
X
COVID-19 SUPPORT
During this uncertain time, one thing remains certain—our commitment to supporting you.
Click here for COVID-19 resources for your practice.
X
Product Information Training Practice resources Ordering Rewards Results

FOR US HEALTHCARE PROFESSIONALS

PRODUCT INFORMATION TRAINING PRACTICE RESOURCES ORDERING REWARDS RESULTS
Important Safety Information Patient Safety Information Directions for Use FOR US PATIENTS Contact Us Set Up Account
×
BOTOX® COSMETIC
(onabotulinumtoxinA)
KYBELLA®
(deoxycholic acid) injection 10 mg/ml
COOLSCULPTING®
LATISSE®
(bimatoprost ophthalmic solution) 0.03%
NATRELLE®
SKINMEDICA®
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM VOLUMA® XC
  • JUVÉDERM VOLBELLA® XC
  • JUVÉDERM VOLLURE™ XC
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM VOLUMA® XC
  • JUVÉDERM VOLBELLA® XC
  • JUVÉDERM VOLLURE™ XC
Read More +
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS
The JUVÉDERM® Collection of Fillers includes JUVÉDERM VOLUMA® XC, JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM VOLBELLA® XC. JUVÉDERM VOLUMA® XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM VOLBELLA® XC is for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.
ONE COLLECTION

A WIDE RANGE OF HYALURONIC ACID FILLERS—EACH DESIGNED FOR SPECIFIC NEEDS1-6

LIFT IT

VOLUMIZE CHEEKS

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area and JUVÉDERM® Ultra XC in the nasolabial folds and lips. Results may vary.

TRAINING
ORDERING
REWARDS
RESULTS
SMOOTH IT

FILL MODERATE TO SEVERE LINES

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area and JUVÉDERM® Ultra XC in the nasolabial folds and lips. Results may vary.

TRAINING
ORDERING
REWARDS
RESULTS
PLUMP IT

ADD FULLNESS TO LIPS

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area and JUVÉDERM® Ultra XC in the nasolabial folds and lips. Results may vary.

TRAINING
ORDERING
REWARDS
RESULTS

CHEEKS • LINES • LIPS

There’s a JUVÉDERM®
for THAT

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area, JUVÉDERM VOLLURE™ XC in the nasolabial folds and marionette lines, and JUVÉDERM® Ultra XC in the lips. Results may vary.

TRAINING
ORDERING
REWARDS
RESULTS
ONE COLLECTION

A WIDE RANGE OF HYALURONIC ACID FILLERS—EACH DESIGNED FOR SPECIFIC NEEDS1-6

LIFT IT

VOLUMIZE CHEEKS

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area and JUVÉDERM® Ultra XC in the nasolabial folds and lips. Results may vary.

SMOOTH IT

FILL MODERATE TO SEVERE LINES

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area and JUVÉDERM® Ultra XC in the nasolabial folds and lips. Results may vary.

PLUMP IT

ADD FULLNESS TO LIPS

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area and JUVÉDERM® Ultra XC in the nasolabial folds and lips. Results may vary.

CHEEKS • LINES • LIPS

There’s a JUVÉDERM® for THAT

Actual patient treated with JUVÉDERM VOLUMA® XC in the cheek area, JUVÉDERM VOLLURE™ XC in the nasolabial folds and marionette lines, and JUVÉDERM® Ultra XC in the lips. Results may vary.

TRAINING
ORDERING
REWARDS
RESULTS
×
CONTOUR
  CONFIDENTLY

JUVÉDERM® VOLUMATM XC is the first and only FDA-approved filler to add volume to the cheek and shape the chin.1,2

Actual patient treated with
JUVÉDERM® VOLUMATM XC
in the cheeks and chin. Results may vary.

References: 1. JUVÉDERM® VOLUMATM XC Directions for Use, June 2020. 2. JUVÉDERM® VOLUMATM XC for Chin Augmentation Patient Label, June 2020.

Logo

JUVÉDERM®, VOLUMATM, and their designs are trademarks of Allergan Holdings France, SAS, an AbbVie company, or its affiliates. © 2020 AbbVie. All rights reserved. hcp.Juvederm.com JUV140308 09/20 007230

A BROAD RANGE OF LONG-LASTING FILLERS1-5

LIFT

LIFT IT

VOLUMIZE CHEEKS

LIFT IT

VOLUMIZE CHEEKS

Actual patient. Results may vary.

Actual patients. Results may vary.


Results last up to 2 years1,*

Correct age-related volume loss in the midface for lift


Learn More

SMOOTH

SMOOTH IT

FILL MODERATE TO SEVERE LINES

SMOOTH IT

FILL MODERATE TO
SEVERE LINES

Actual patient. Results may vary.


Results last up to 18 months2,7,*

Add subtle volume to smooth moderate to severe facial wrinkles and folds


Learn More

FILL

FILL IT

CORRECT MODERATE TO SEVERE LINES

FILL IT

CORRECT MODERATE TO
SEVERE LINES

Actual patient. Results may vary.


Results last beyond 1 year4,*

Fill moderate to severe facial wrinkles and folds


Learn More

SOFTEN

SOFTEN IT

CORRECT PERIORAL LINES AND VOLUMIZE LIPS

SOFTEN IT

CORRECT PERIORAL LINES; ENHANCE LIP FULLNESS

Actual patient. Results may vary.


Results last up to 1 year3,*

Soften the appearance of perioral lines and add subtle volume to the lips


Learn More

PLUMP

PLUMP IT

ADD DESIRED FULLNESS TO LIPS

PLUMP IT

ADD DESIRED
FULLNESS TO LIPS

Actual patient. Results may vary.


Results last up to 1 year5,8,*

Plump the lips; correct moderate to severe facial wrinkles and folds


Learn More

Results last up to 2 years1,*

Correct age-related volume loss in the midface for lift


Learn More

Results last up to 18 months2,7,*

Add subtle volume to smooth moderate to severe facial wrinkles and folds


Learn More

Results last beyond 1 year4,*

Fill moderate to severe facial wrinkles and folds


Learn More

Results last up to 1 year3,*

Soften the appearance of perioral lines and add subtle volume to the lips


Learn More

Results last up to 1 year5,8,*

Plump the lips; correct moderate to severe facial wrinkles and folds


Learn More

*With optimal treatment.

Clancy
Kim
Anne
Michelle
Thomas
Erin
Bridgham
Lou
Jack
Brenda
Chanita
Lorna
Alicia
Monique
Abbey
Catherine
Connie
Eva
Laura
Kris
Joyce
Michael
Nancy
Karen
Kathy
Anise
Sachiko
Tami
Jennifer
Tammy
Sherilee
Brenda
Chanita
Lorna
Karla
Tammy
Kris
Clancy
Michelle
Anne
Alicia
Monique
Joyce
Abbey
Michael
Jennifer
Kim
Lisa
Erin
Bridgham
Thomas
Catherine
Connie
Eva
Laura
Nancy
Karen
Kathy
Anise
Sachiko
Tami
Sherilee
Jodi
Lou
Jack
SEE THE DIFFERENCE
AGE 20s 30s 40s 50s 60s
All
Name
BEFORE
BEFORE
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 1.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 0.6 mL of JUVÉDERM® Ultra XC was injected into facial wrinkles and folds. A total of 0.9 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 1 year after treatment. A total of 1.1 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 1 year after treatment. A total of 1.2 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and vermilion border) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.6 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.7 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 0.9 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 18 months after treatment. A total of 2.3 mL of JUVÉDERM VOLLURE™ XC was injected into the nasolabial folds, oral commissures, and marionette lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 1 year after treatment. A total of 1.2 mL of JUVÉDERM VOLBELLA® XC was injected into the lips (vermilion body and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 3 months after treatment. A total of 2.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds. A total of 0.4 mL of JUVÉDERM® Ultra XC was injected into the marionette lines.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.4 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 2.9 mL of JUVÉDERM VOLLURE™ XC was injected into the nasolabial folds and marionette lines. A total of 2.2 mL of JUVÉDERM VOLBELLA® XC was injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns), and into the perioral lines.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.1 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 0.7 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body, Cupid’s bow, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.0 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds. A total of 1.5 mL of JUVÉDERM® Ultra XC was injected into the nasolabial folds and oral commissures. A total of 1.3 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.5 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and vermilion border) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 3 months after treatment. A total of 1.6 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, and Cupid's bow) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.5 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds and oral commissures. A total of 1.4 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body, vermilion border, and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.2 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into the nasolabial folds, oral commissures, and marionette lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 18 months after treatment. A total of 3.8 mL of JUVÉDERM VOLLURE™ XC was injected into the nasolabial folds, oral commissures, and marionette lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 3 months after treatment. A total of 3.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 0.5 mL of JUVÉDERM® Ultra XC was injected into facial wrinkles and folds. A total of 1.8 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 2.2 mL of JUVÉDERM® Ultra XC was also injected into facial wrinkles and folds.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 months after treatment. A total of 2.3 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient who received a 3-syringe treatment with JUVÉDERM® Ultra XC for the nasolabial folds and marionette lines. One syringe = 1.0 mL of JUVÉDERM® Ultra XC.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 months after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds and oral commissures.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 1.8 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 8.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.3 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, marionette lines, and oral commissures. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into the nasolabial folds.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 3.8 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.4 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 0.7 mL of JUVÉDERM® Ultra XC was also injected into the oral commissures.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 4.8 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into facial wrinkles and folds.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.1 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation, and into the perioral lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.2 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 0.7 mL of JUVÉDERM® Ultra XC was injected into facial wrinkles and folds. A total of 1.7 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 4.7 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.3 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.8 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation, and into the perioral lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.2 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation, and into the perioral lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient who received a 3-syringe treatment with JUVÉDERM® Ultra XC for the nasolabial folds. One syringe = 1.0 mL of JUVÉDERM® Ultra XC.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 2 years after treatment. A total of 3.5 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
SEE THE DIFFERENCE
AGE
20s
30s
40s
50s
60s
All
Name
Before
SLIDE
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.2 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and vermilion border) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.6 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.7 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 0.9 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.2 mL of JUVÉDERM VOLBELLA® XC was injected into the lips (vermilion body and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 3 months after treatment. A total of 2.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds. A total of 0.4 mL of JUVÉDERM® Ultra XC was injected into the marionette lines.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.2 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation, and into the perioral lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 1.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 0.6 mL of JUVÉDERM® Ultra XC was injected into facial wrinkles and folds. A total of 0.9 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.1 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.2 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 0.7 mL of JUVÉDERM® Ultra XC was injected into facial wrinkles and folds. A total of 1.7 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 4.7 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.3 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.4 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 2.9 mL of JUVÉDERM VOLLURE™ XC was injected into the nasolabial folds and marionette lines. A total of 2.2 mL of JUVÉDERM VOLBELLA® XC was injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns), and into the perioral lines.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.1 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 0.7 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body, Cupid’s bow, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.0 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds. A total of 1.5 mL of JUVÉDERM® Ultra XC was injected into the nasolabial folds and oral commissures. A total of 1.3 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.5 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and vermilion border) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.5 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds and oral commissures. A total of 1.4 mL of JUVÉDERM® Ultra XC was injected into the lips (vermilion body, vermilion border, and philtral columns).
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.2 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into the nasolabial folds, oral commissures, and marionette lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 3.8 mL of JUVÉDERM VOLLURE™ XC was injected into the nasolabial folds, oral commissures, and marionette lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 3 months after treatment. A total of 3.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 0.5 mL of JUVÉDERM® Ultra XC was injected into facial wrinkles and folds. A total of 1.8 mL of JUVÉDERM® Ultra XC was also injected into the lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns).

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 months after treatment. A total of 2.3 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 2.2 mL of JUVÉDERM® Ultra XC was also injected into facial wrinkles and folds.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 3 months after treatment. A total of 1.6 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, and Cupid's bow) for lip augmentation.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 months after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds and oral commissures.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 1.8 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 8.6 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.3 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, marionette lines, and oral commissures. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into the nasolabial folds.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 3.8 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area. A total of 3.4 mL of JUVÉDERM® Ultra Plus XC was injected into the nasolabial folds, oral commissures, and marionette lines. A total of 0.7 mL of JUVÉDERM® Ultra XC was also injected into the oral commissures.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 4.8 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into facial wrinkles and folds.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.1 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation, and into the perioral lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.8 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation, and into the perioral lines.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.0 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient who received a 3-syringe treatment with JUVÉDERM® Ultra XC for the nasolabial folds. One syringe = 1.0 mL of JUVÉDERM® Ultra XC.
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 3.5 mL of JUVÉDERM VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.1
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.3 mL of JUVÉDERM VOLLURE™ XC was injected into the nasolabial folds, oral commissures, and marionette lines.
Actual patient. Results may vary.
Unretouched photos of paid patient who received a 3-syringe treatment with JUVÉDERM® Ultra XC for the nasolabial folds and marionette lines. One syringe = 1.0 mL of JUVÉDERM® Ultra XC.

practice resources

Online and hands-on injector training to help you optimize patient outcomes and pursue clinical excellence.
Learn More
Download patient educational tools and marketing materials for your practice.
Learn More
Our professional loyalty program: The more you purchase, the greater the rebates.
Learn More
AllēSM is the new and improved loyalty program by Allergan AestheticsTM.
Learn More

JUVÉDERM® ON INSTAGRAM®

FOLLOW US
References: 1. JUVÉDERM VOLUMA® XC Directions for Use, September 2016. 2. JUVÉDERM VOLLURE™ XC Directions for Use, March 2017. 3. JUVÉDERM VOLBELLA® XC Directions for Use, July 2017. 4. JUVÉDERM® Ultra Plus XC Directions for Use, May 2016. 5. JUVÉDERM® Ultra XC Directions for Use, May 2016. 6. Pierre S, Liew S, Bernardin A. Basics of dermal filler rheology. Dermatol Surg. 2015;41(suppl 1):120S-126S. 7. JUVÉDERM VOLLURE™ XC Patient Label, March 2017. 8. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for JUVÉDERM® vs ZYPLAST® Nasolabial Fold Study Group. JUVÉDERM® injectable gel: A multicenter, double-blind, randomized study of safety and effectiveness. Aesthetic Surg J. 2008;28(1):17-23.
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS AND IMPORTANT SAFETY INFORMATION
The JUVÉDERM® Collection of Fillers includes JUVÉDERM® VOLUMA™ XC, JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM® VOLBELLA™ XC. JUVÉDERM® VOLUMA™ XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit and for augmentation of the chin region to improve the chin profile in adults over the age of 21. JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM® VOLBELLA™ XC is for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.
JUVÉDERM® Collection of Fillers Important Information
INDICATIONS

JUVÉDERM® VOLUMA™ XC is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.


JUVÉDERM® VOLLURE™ XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.


JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).


JUVÉDERM® VOLBELLA™ XC injectable gel is indicated for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.


JUVÉDERM® Ultra XC injectable gel is indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.
WARNINGS
•Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
•Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled
PRECAUTIONS
•To minimize the risk of potential complications, these products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy and product use in indicated areas
•The potential risks of soft-tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
•The safety and effectiveness for the treatment of anatomic regions other than the mid-face, chin, and prejowl sulcus regions with JUVÉDERM® VOLUMA™ XC; facial wrinkles and folds with JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC; and the lips and perioral area with JUVÉDERM® VOLBELLA™ XC and JUVÉDERM® Ultra XC have not been established in controlled clinical studies
•The safety for use of these products during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
•The safety for use of JUVÉDERM® VOLUMA™ XC has been established in patients between 35 and 65 years of age in cheek augmentation and for patients between 22 and 80 years of age for chin augmentation
•The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and JUVÉDERM® VOLLURE™ XC and JUVÉDERM® VOLBELLA™ XC in patients under 22 years, has not been established
•As with all transcutaneous procedures, dermal filler implantation carries a risk of infection
•Use dermal fillers with caution in patients on immunosuppressive therapy
•Patients who are using products that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
•Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
•The safety for use of JUVÉDERM® VOLUMA™ XC injectable gel in patients with very thin skin in the mid-face has not been established
•The safety of JUVÉDERM® VOLUMA™ XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI
•JUVÉDERM® VOLUMA™ XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
•The effect of JUVÉDERM® VOLUMA™ XC injection into the chin on facial hair growth has not been studied
•Patients may experience late onset nodules with use of dermal fillers including JUVÉDERM® VOLUMA™ XC
•Patients may experience late onset adverse events with use of dermal fillers







ADVERSE EVENTS
The most commonly reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA™ XC, dryness was also reported. The majority were mild or moderate in severity. For JUVÉDERM® VOLUMA™ XC, most resolved within 2 to 4 weeks. For JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, or JUVÉDERM® Ultra XC, most resolved within 14 days; and for JUVÉDERM® VOLBELLA™ XC, most resolved within 30 days.
To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan at 1-800-433-8871. Please visit JuvedermDFU.com for more information.
Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

Privacy Statement | California Privacy Policy | Terms of Use
© 2020 Allergan. All rights reserved. All trademarks are the property of their respective owners.
hcp.Juvederm.com JUV106549-v5 08/20 007232

This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn). Read More By clicking "Accept" you understand that you are directing Allergan to disclose your personal information, including internet tracking data (like cookies and the IP address you used to access this website), to these third parties for the purposes stated above. You can still use this website if you do not click "Accept," but your experience may be different. For more information, including a list of the categories of third parties to whom we disclose your personal information, please refer to our California Privacy Policyopens in a new window or for additional options please check your browser’s settings. Read Less

Accept
×